Past, present, and future efforts to enhance the efficacy of cord blood hematopoietic cell transplantation [version 1; peer review: 3 approved]

Xinxin Huang, Bin Guo, Maegan Capitano, Hal E. Broxmeyer

Research output: Contribution to journalReview article

Abstract

Cord blood (CB) has been used as a viable source of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) in over 35,000 clinical hematopoietic cell transplantation (HCT) efforts to treat the same variety of malignant and non-malignant disorders treated by bone marrow (BM) and mobilized peripheral blood (mPB) using HLA-matched or partially HLA-disparate related or unrelated donor cells for adult and children recipients. This review documents the beginning of this clinical effort that started in the 1980's, the pros and cons of CB HCT compared to BM and mPB HCT, and recent experimental and clinical efforts to enhance the efficacy of CB HCT. These efforts include means for increasing HSC numbers in single CB collections, expanding functional HSCs ex vivo, and improving CB HSC homing and engraftment, all with the goal of clinical translation. Concluding remarks highlight the need for phase I/II clinical trials to test the experimental procedures that are described, either alone or in combination.

Original languageEnglish (US)
Article number1833
JournalF1000Research
Volume8
DOIs
StatePublished - Oct 31 2019

Fingerprint

Peer Review
Cell Transplantation
Hematopoietic Stem Cells
Fetal Blood
Blood Cells
Blood
Stem cells
Bone Marrow
Unrelated Donors
Phase II Clinical Trials
Clinical Trials, Phase I
Bone
Cell Count

Keywords

  • Collection/Processing of Cord Blood
  • Cord Blood
  • Ex-vivo Expansion
  • Hematopoietic Cell Transplantation
  • Hematopoietic Progenitor Cells
  • Hematopoietic Stem Cells
  • Homing
  • Influence of Oxygen Tension
  • Regulation of Hematopoiesis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Past, present, and future efforts to enhance the efficacy of cord blood hematopoietic cell transplantation [version 1; peer review : 3 approved]. / Huang, Xinxin; Guo, Bin; Capitano, Maegan; Broxmeyer, Hal E.

In: F1000Research, Vol. 8, 1833, 31.10.2019.

Research output: Contribution to journalReview article

@article{6d481f7c6a454b188ada61bdb0ad31af,
title = "Past, present, and future efforts to enhance the efficacy of cord blood hematopoietic cell transplantation [version 1; peer review: 3 approved]",
abstract = "Cord blood (CB) has been used as a viable source of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) in over 35,000 clinical hematopoietic cell transplantation (HCT) efforts to treat the same variety of malignant and non-malignant disorders treated by bone marrow (BM) and mobilized peripheral blood (mPB) using HLA-matched or partially HLA-disparate related or unrelated donor cells for adult and children recipients. This review documents the beginning of this clinical effort that started in the 1980's, the pros and cons of CB HCT compared to BM and mPB HCT, and recent experimental and clinical efforts to enhance the efficacy of CB HCT. These efforts include means for increasing HSC numbers in single CB collections, expanding functional HSCs ex vivo, and improving CB HSC homing and engraftment, all with the goal of clinical translation. Concluding remarks highlight the need for phase I/II clinical trials to test the experimental procedures that are described, either alone or in combination.",
keywords = "Collection/Processing of Cord Blood, Cord Blood, Ex-vivo Expansion, Hematopoietic Cell Transplantation, Hematopoietic Progenitor Cells, Hematopoietic Stem Cells, Homing, Influence of Oxygen Tension, Regulation of Hematopoiesis",
author = "Xinxin Huang and Bin Guo and Maegan Capitano and Broxmeyer, {Hal E.}",
year = "2019",
month = "10",
day = "31",
doi = "10.12688/f1000research.20002.1",
language = "English (US)",
volume = "8",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Past, present, and future efforts to enhance the efficacy of cord blood hematopoietic cell transplantation [version 1; peer review

T2 - 3 approved]

AU - Huang, Xinxin

AU - Guo, Bin

AU - Capitano, Maegan

AU - Broxmeyer, Hal E.

PY - 2019/10/31

Y1 - 2019/10/31

N2 - Cord blood (CB) has been used as a viable source of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) in over 35,000 clinical hematopoietic cell transplantation (HCT) efforts to treat the same variety of malignant and non-malignant disorders treated by bone marrow (BM) and mobilized peripheral blood (mPB) using HLA-matched or partially HLA-disparate related or unrelated donor cells for adult and children recipients. This review documents the beginning of this clinical effort that started in the 1980's, the pros and cons of CB HCT compared to BM and mPB HCT, and recent experimental and clinical efforts to enhance the efficacy of CB HCT. These efforts include means for increasing HSC numbers in single CB collections, expanding functional HSCs ex vivo, and improving CB HSC homing and engraftment, all with the goal of clinical translation. Concluding remarks highlight the need for phase I/II clinical trials to test the experimental procedures that are described, either alone or in combination.

AB - Cord blood (CB) has been used as a viable source of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) in over 35,000 clinical hematopoietic cell transplantation (HCT) efforts to treat the same variety of malignant and non-malignant disorders treated by bone marrow (BM) and mobilized peripheral blood (mPB) using HLA-matched or partially HLA-disparate related or unrelated donor cells for adult and children recipients. This review documents the beginning of this clinical effort that started in the 1980's, the pros and cons of CB HCT compared to BM and mPB HCT, and recent experimental and clinical efforts to enhance the efficacy of CB HCT. These efforts include means for increasing HSC numbers in single CB collections, expanding functional HSCs ex vivo, and improving CB HSC homing and engraftment, all with the goal of clinical translation. Concluding remarks highlight the need for phase I/II clinical trials to test the experimental procedures that are described, either alone or in combination.

KW - Collection/Processing of Cord Blood

KW - Cord Blood

KW - Ex-vivo Expansion

KW - Hematopoietic Cell Transplantation

KW - Hematopoietic Progenitor Cells

KW - Hematopoietic Stem Cells

KW - Homing

KW - Influence of Oxygen Tension

KW - Regulation of Hematopoiesis

UR - http://www.scopus.com/inward/record.url?scp=85074960499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074960499&partnerID=8YFLogxK

U2 - 10.12688/f1000research.20002.1

DO - 10.12688/f1000research.20002.1

M3 - Review article

C2 - 31723413

AN - SCOPUS:85074960499

VL - 8

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 1833

ER -